Drug Profile
Eculizumab biosimilar - Amgen
Alternative Names: ABP 959; BEKEMVLatest Information Update: 17 Jan 2024
Price :
$50
*
At a glance
- Originator Amgen
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Paroxysmal nocturnal haemoglobinuria
- No development reported Haemolytic uraemic syndrome
Most Recent Events
- 09 Dec 2023 Pharmacokinetics data from a phase III DAHLIA trial in Paroxysmal nocturnal haemoglobinuria presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 03 Aug 2023 US FDA accepts BLA for eculizumab biosimilar for Paroxysmal nocturnal haemoglobinuria for review
- 27 Apr 2023 Preregistration for Paroxysmal nocturnal haemoglobinuria in USA (IV)